Object's details: Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)

Provider:Repozytorium Uniwersytetu Łódzkiego

Description

Title:
Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)
Creator:
Rogalska, Aneta
Contributor:
Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236, Lodz, Poland.;
aneta.rogalska@biol.uni.lodz.pl
Description:
Resistance to olaparib inevitably develops in ovarian cancer (OC) patients, highlighting the necessity for effective strategies to improve its efficacy. Here, we established a novel olaparib-resistant patient-derived xenograft model of high-grade serous OC with BRCA1/2 mutations and examined the molecular characteristics of acquired resistance and resensitization to olaparib in treatment-naïve tumors in vivo. Olaparib-resistant xenografts were treated with olaparib, ATR inhibitor (ATRi, ceralasertib), CHK1 inhibitor (CHK1i, MK-8776) or their combinations. Proliferation, apoptosis, ATR/CHK1 activity, PARP signaling, DNA damage response (DDR), epithelial-to-mesenchymal transition (EMT), and MDR1 expression, were examined via RT-qPCR, western blot, and immunohistochemistry. Resistant tumors exhibited defects in PARP and ATR/CHK1 signaling, accompanied by altered expression of proteins involved in DDR and EMT. Olaparib rechallenge combined with ATR/CHK1 inhibitors showed promising synergistic effects on tumor growth inhibition. Mechanistically, combined treatments suppressed tumor proliferation without increasing apoptosis or necrosis, while inducing tumor cell vacuolization indicative of cell death. ATRi combined with olaparib induced or augmented downregulation of ATR, CHK1, PARP1, PARG, BRCA1, γH2AX, and PARylated protein expression, while reversing olaparib-induced upregulation of vimentin, BRCA2, and 53BP1. Our collective findings indicate that ATR/CHK1 pathway inhibition restores the olaparib efficacy in resistant BRCA1/2MUT high-grade serous OC, highlighting promising approach for olaparib rechallenge of non-responsive patients. Uncovered mechanisms might improve our understanding of acquisition and overcoming resistance to olaparib in ovarian cancer.;
National Science Centre, Poland (Project grant number: Sonata Bis 2019/34/E/NZ7/00056).
Object availability:
free access
Rights:
CC0 1.0 uniwersalna;
http://creativecommons.org/publicdomain/zero/1.0
Date:
2025.01.27;
2024
Type:
Dataset
Language:
English
Format:
application/octet-stream
Subject:
ATR/CHK1 pathway;
Olaparib resistance;
Patient-derived xenograft;
Ovarian cancer;
Resensitization
Identifier: http://hdl.handle.net/11089/54405
Data provider:
Repozytorium Uniwersytetu Łódzkiego

Similar objects

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)

Creator:Rogalska, Aneta

Date:2025.01.27 | 2024

Type:text

Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors, Sonata Bis 2019/34/E/NZ7/00056, Sonata Bis-9 (dataset)

Creator:Rogalska, Aneta

Date:2024.07.02 | 2024

Type:text

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival, Sonata Bis 2019/34/E/NZ7/00056, Sonata Bis-9 (dataset)

Creator:Rogalska, Aneta

Date:2023.04.11 | 2020.10.01

Type:text

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival

Creator:Biegała, Łukasz | Gajek, Arkadiusz | Marczak, Agnieszka | Rogalska, Aneta

Date:2023.05.08 | 2023

Type:image

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell Lines

Creator:Rogalska, Aneta

Date:2025.02.27 | 2025

Type:text

PARP Inhibitors in the Treatment of Ovarian Cancer: a review of the latest research

Creator:Zuzak, Andrzej Paweł | Satora, Małgorzata | Cieślik-Porębska, Magdalena | Kułak, Krzysztof | Niewiadomska , Jagoda

Date:2025.02.21

Type:text

Endometriosis and ovarian cancer - what they have in common?

Date:2020.08.17

Type:text

Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells, Sonata Bis 2019/34/E/NZ7/00056, Sonata Bis-9 (dataset)

Creator:Rogalska, Aneta

Date:2024.03.07 | 2023

Type:text

Federacja Bibliotek Cyfrowych

Object's details: Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)

Description

Similar objects